Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer.
Molecular marker analyses aiming a more accurate disease characterization and risk stratification of cancer patients provided several promising marker candidates in the last few years. However, recent reviews underlined the paramount importance of validation, since many of the initially promising results could not be confirmed in independent patient cohorts. If serum or plasma is a more appropriate sample to test for prognostic markers is a matter of debate. We recently found serum MMP-7 levels to correlate with poor patients' prognosis in urinary bladder cancer. In this study, we examined associations of the MMP-7 plasma levels with clinical follow-up data in an independent cohort of bladder cancer patients to validate our former results and to assess if plasma is also suitable for MMP-7 analysis. Plasma levels of 97 patients and 22 controls were analyzed, using enzyme-linked immunosorbent assay. Associations between MMP-7 plasma concentrations and clinical data were assessed applying both univariate and multivariate analysis. Plasma MMP-7 levels were significantly higher in patients than in controls. Similarly to our former findings in sera, high MMP-7 plasma levels proved to be significant and independent predictors of both overall and disease-specific survival. In addition, we observed a metastasis-specific difference in MMP-7 levels between serum and plasma. In summary, we confirmed the prognostic relevance of circulating MMP-7 levels in an independent cohort of patients and concluded that circulating MMP-7 levels may help to identify bladder cancer patients at high-risk of disease progression who could benefit from an adjuvant chemotherapy or from an extended lymph node dissection.
Department of Urology, University of Duisburg-Essen, Hufelandstr 55, 45147 Essen, Germany.
Tibor
T
Szarvas
Tobias
T
Jäger
Markus
M
Becker
Stephan
S
Tschirdewahn
Christian
C
Niedworok
Ilona
I
Kovalszky
Herbert
H
Rübben
Süleyman
S
Ergün
Frank
F
vom Dorp
D014408:Biomarkers, Tumor / Q000097:blood*; D002295:Carcinoma, Transitional Cell / Q000097:blood* / Q000401:mortality; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D020783:Matrix Metalloproteinase 7 / Q000097:blood*; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D001749:Urinary Bladder Neoplasms / Q000097:blood* / Q000401:mortality
D014408:Biomarkers, Tumor; D020783:Matrix Metalloproteinase 7
Urologe A. 2009 Jan;48(1):51-3
19048222
J Immunol. 1998 Dec 15;161(12):6845-52
9862716
Int J Cancer. 2007 Sep 1;121(5):1066-71
17487834
BJU Int. 2011 Apr;107(7):1069-73
20825402
Stat Med. 2000 Feb 29;19(4):453-73
10694730
Clin Chem. 2008 Apr;54(4):772-3
18375496
J Clin Oncol. 2001 Feb 15;19(4):1118-27
11181677
J Cancer Res Clin Oncol. 1991;117(2):144-50
1848860
Tumour Biol. 2010 Jun;31(3):149-55
20300917
J Clin Epidemiol. 2003 Sep;56(9):826-32
14505766
Curr Biol. 1999 Dec 16-30;9(24):1441-7
10607586
Br J Cancer. 2009 Apr 21;100(8):1219-29
19367280
Cancer Sci. 2010 May;101(5):1300-8
20180812
J Clin Oncol. 2003 Feb 15;21(4):690-6
12586807
Clin Cancer Res. 2007 Jun 15;13(12):3545-51
17575217
Carcinogenesis. 2006 May;27(5):1113-20
16474169
J Urol. 2006 Aug;176(2):486-92; discussion 491-2
16813874
Ann Surg Oncol. 2009 May;16(5):1412-20
19259740
Cancer Sci. 2008 Jun;99(6):1188-94
18422740
Int J Cancer. 2011 Mar 15;128(6):1486-92
20473942
Blood. 2009 Mar 5;113(10):2363-9
18974372
Br J Cancer. 2002 Feb 1;86(3):417-23
11875709
J Cell Sci. 2001 Jan;114(Pt 1):111-118
11112695